- Details
- Manish Patel joins Sam Chang to discuss the development of centers of excellence for the treatment of major urological cancers, specifically focusing on radical cystectomy. He explains how the UK's centralization of radical cystectomy in 2002 led to significant improvements in care and better survival rates. In Australia, 50 centers were doing radical cystectomies, but 39 were doing less than four...
|
- Details
- Ewan Gibb, a PhD scientist, discusses the Decipher Bladder clinical test, a molecular subtyping assay for bladder cancer that predicts the risk of upstaging, identifies high-risk neuroendocrine-like disease and determines the benefit from neoadjuvant chemotherapy. The test breaks a patient's tumor into one of five subtypes and recognizes luminal and non-luminal categories, with neuroendocrine bein...
|
- Details
- In a detailed discussion between Sam Chang and Sarah Psutka, they explore the SunRISe-4 trial, a phase II study investigating the combination of TAR-200 agent with cetrelimab in muscle invasive bladder cancer patients. The trial targets those who are due for radical cystectomy but cannot or refuse the toxic cisplatin-based neoadjuvant chemotherapy, the current standard of care. The study focuses o...
|
- Details
- Gary Deng discusses his book "The Wellness Principles" in a conversation with Alicia Morgans. The book, which Dr. Deng describes as a wellness guide rather than a cookbook, is aimed at improving the quality of life for cancer patients by encouraging healthy lifestyles. Dr. Deng argues against extreme diet plans, instead promoting balanced, quick-to-make, and delicious meals. In particular, he shar...
|
- Details
- In this discussion, Ashish Kamat welcomes John Sfakianos. Dr. Sfakianos, recipient of the prestigious BCAN Research Innovation Award, presents his award-winning research on non-muscle invasive bladder cancer and BCG resistance. He delves into the complex interactions within the tumor microenvironment, using novel technologies like spatial transcriptomics to study the diverse roles of various immun...
|
- Details
- Adam ElNaggar presents details about Signatera, a personalized tumor-informed molecular residual disease test. The focus of his talk includes explaining the prognostic and predictive value of circulating tumor DNA (ctDNA) and its role in clinical trial design. Dr. ElNaggar emphasizes that Signatera is specific to an individual's tumor, and its methodology involves whole exome sequencing of both tu...
|
- Details
- Ashish Kamat and Kari Tikkinen discuss guidelines on thromboprophylaxis in urological surgery. Dr. Tikkinen gives a step-by-step guide through deciding to use thromboprophylaxis, starting with demonstrating that prophylaxis works and then discussing what constitutes a need for thromboprophylaxis for the patient. They also discuss cases where the guidelines may falter and how to troubleshoot in tho...
|
- Details
- Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus Calmette-Guérin...
|
- Details
- Arlene Siefker-Radtke discusses the perioperative management of urothelial cancer, focusing on the balance between efficacy and toxicity in treatments. She reflects on the standard use of cisplatin-based chemotherapy, its associated long-term side effects, and how nearly half of urothelial cancer patients find this treatment intolerable. Dr. Siefker-Radtke touches on the ongoing debate between Dos...
|
- Details
- Tamer Aboushwareb, Vice President of Medical Affairs, Pacific Edge, Ltd provides an overview of the Cxbladder Monitor urine-based cancer surveillance test and is joined by Neal Shore and Josh Meeks for a discussion on the clinical implications of the use of this test. Several supportive publications are highlighted and Drs Shore, Meeks, and Aboushwareb discuss the Cxbladder Monitor algorithm, its...
|
